Physicians Slow to Implement HPV Vaccination and Cervical Cancer Screening Guidelines
San Diego, CA, July 9, 2013
Results of survey of obstetrician-gynecologists published in the
American Journal of Preventive Medicine
Results of survey of obstetrician-gynecologists published in the American Journal of Preventive Medicine
Recent breakthroughs in cervical cancer prevention have resulted in new vaccination and cervical cancer screening guidelines. Recommendations do not always translate into practice, however. Less than one third of obstetrician-gynecologists vaccinate their eligible patients against the human papilloma
virus (HPV), and only half adhere to cervical cancer prevention guidelines published three years previously, according to a survey published this month in the American
Journal of Preventive Medicine.
Vaccination against HPV has been recommended for women aged 11–26 years since 2006. In 2009, the American Congress of Obstetricians and Gynecologists (ACOG) issued guidelines recommending the initiation of Pap tests for 21 year-old women, decreasing the frequency of screening to biennial screening between ages 21 and 29 years, triennial screening for women aged 30 years or more with either prior normal Paps or negative concurrent HPV co-testing, and discontinuation of screening at age ≥70 years or after hysterectomy for benign indications.
The investigators found that patient and physician interactions may pose important barriers to guideline implementation. "In the current survey and others, providers stated that the largest barrier to HPV vaccination was patients and parents declining to receive the vaccine. However, studies indicate that most patients support HPV vaccination, and that a strong physician recommendation is the most important determinant of vaccine uptake in young women," says lead investigator Rebecca B. Perkins, MD, MSc, of the Boston University School of Medicine.
Investigators queried 1,000 obstetrician-gynecologists, all members of ACOG, about their screening and vaccination practices, as well as barriers that prevented physicians from following the 2009 ACOG guidelines. A total of 366 responses were analyzed.
The investigators found low rates of HPV vaccination. Although 92% of respondents offered HPV vaccination to patients, only 27% estimated that most eligible patients received vaccination. The most commonly cited barriers to HPV vaccination were parent and patient refusals. Most practitioners (96%) would recommend HPV vaccination to a hypothetical 13 year-old patient, but only 73% said they would recommend vaccination to an 11 year-old patient.
Approximately half of the respondents followed guidelines to begin cervical cancer screening at age 21, discontinue screening at age 70 or after hysterectomy, and to utilize Pap and HPV co-testing appropriately.
Most physicians continued to recommend annual Pap test screening (74% ages 21-29, 53% ages 30 and above). Although the respondents were personally comfortable with extended screening intervals, they felt that patients were uncomfortable with extended screening intervals and were concerned that patients would not come for annual exams if a Pap were not offered. Solo practitioners were less likely to follow both vaccination and screening guidelines than those in group practices.
About 45% of practitioners offered Pap and HPV co-testing to women aged 30 years upwards, 21% offered this only if requested by the patient, 11% screened all women with both tests, and 23% did not offer HPV testing.
Only 16 physicians (4%) reported adherence to all ACOG 2009 guidelines for cervical cancer screening.
Since this survey was completed, new guidelines have been issued in 2012 by the US Preventive Services Task Force, American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology, which have subsequently been endorsed by the American Congress of Obstetricians and Gynecologists, recommending triennial Paps for women aged 21–29 years and co-testing with Pap and HPV tests at five-year intervals for women aged 30–65 years, regardless of whether they have received HPV vaccination.
"Our survey which was conducted prior to the new 2012 guidelines reveals limited implementation of HPV vaccination and cervical cancer screening guidelines six and three years, respectively, after these guidelines were published. It may portend very slow uptake of these guidelines unless efforts are made to hasten implementation," comments Dr. Perkins. "In the light of persistently low HPV vaccination rates, and new guidelines recommending Pap and HPV co-testing at five-year intervals, programs to educate physicians and patients on the evidence behind universal HPV vaccination, and extended-interval cervical cancer screening with Pap and HPV co-testing could help improve the quality of cervical cancer prevention."
In an Editorial in the same issue, Russell Harris, MD, MPH, and Stacey Sheridan, MD, MPH, from the Department of Medicine, Division of General Medicine and Clinical Epidemiology, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, observe that the US Preventive Services Task Force (USPSTF), sometimes joined by other professional and advocacy groups, has continued to recommend less screening for breast, colorectal, prostate, and cervical cancer, and that there has been a growing chorus of voices that suggest a coming change in the attitudes of the public and the profession towards screening.
"The new message boils down to this: Screening is not the unqualified good that we have advertised it to be. It has clear potential harms as well as benefits, and these must be carefully weighed before a rational decision about screening can be made. Sometimes screening does more good than harm, but at other times it does more harm than good," they write.
"As shown by Perkins et al., many gynecologists continue to report starting cervical cancer screening before age 21 and not stopping at age 65; continuing to screen after hysterectomy for benign indications; and screening annually rather than every three years. This finding is in agreement with other studies of both physicians and the public. We have not yet reached a tipping point of professional or public opinion; we are only witnessing increased discussion and open dissent with prior policies. The battle for the hearts and minds of the profession and the public is ongoing," Harris and Sheridan conclude.
# # #
Notes for Editors
"Challenges in Cervical Cancer Prevention: A Survey of U.S. Obstetrician-Gynecologists," by Rebecca B. Perkins, MD, MSc; Britta L Anderson, PhD; Sherri Sheinfeld Gorin, PhD; Jay A Schulkin, PhD (DOI: 10.1016/j.amepre.2013.03.019).
"The Times They (May) Be A-Changin': Too Much Screening Is a Health Problem," by Russell Harris, MD, MPH; Stacey Sheridan, MD, MPH (DOI: 10.1016/j.amepre.2013.05.002).
Both articles appear in the American Journal of Preventive Medicine, Volume 45, Issue 2 (August 2013), published by Elsevier.
Full text of the articles is available to credentialed journalists upon request; contact Charlotte Seidman at +1 858 534 9340 or eAJPM@ucsd.edu. Journalists wishing to interview Dr. Perkins should contact Gina Orlando, Public Relations Associate, Boston University School of Medicine, at +1 617 638 8490 or Gina.Orlando@bmc.org. Dr. Harris may be contacted via Kathy Neal at +1 919 740 5673 or email@example.com.
About the American Journal of Preventive
The American Journal of Preventive Medicine (www.ajpmonline.org) is the official journal of The American College of Preventive Medicine (www.acpm.org) and the Association for Prevention Teaching and Research (http://www.aptrweb.org/). It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials.
The American Journal of Preventive Medicine, with an Impact Factor of 3.945, is ranked 15th out of 158 Public, Environmental, and Occupational Health titles and 18th out of 151 General & Internal Medicine titles according to the 2012 Journal Citation Reports® published by Thomson Reuters.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+1 858 534 9340